Paul Grayson

Paul A. Grayson was the founder of Senomyx, Inc., founded in 1998, where the title held was President & Chief Executive Officer from 1998 to 2003.
Mr. Grayson was the founder of Fate Therapeutics, Inc., founded in 2007, where the title held was President & Chief Executive Officer from 2008 to 2011.
Current jobs include President & Chief Executive Officer at RuiYi, Inc. (China); President, Chief Executive Officer & Director at Radionetics Oncology, Inc. since 2023; Chairman at Skye Bioscience, Inc. since 2024; and Member at Aurora Biosciences Corp.
Former jobs include President, Chief Executive Officer & Director at Bird Rock Bio Sub, Inc. from 2011 to 2023; President, Chief Executive Officer & Director at Tentarix Biotherapeutics, Inc. from 2020 to 2023; President & Chief Executive Officer at Tentarix Biotherapeutics LP from 2020 to 2024; Chairman at Naviscan, Inc.; Chairman at CalciMedica Subsidiary, Inc.; Managing Director at Sanderling Management CO LLC from 2003 to 2008; Director at Chimerix, Inc.; Director at Ren Pharmaceuticals, Inc.; Director at Apoptos, Inc.; Director at Receptos LLC; Director at TempestTx, Inc.; Director at Progenitor Labs Ltd.; Director at Contineum Therapeutics, Inc.; and Venture Partner at Versant Venture Management LLC from 2018 to 2024.
Education includes an undergraduate degree from the University of California, Los Angeles, conferred in 1986, and an MBA from the University of California, Irvine, conferred in 1989.